Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients

Clinical Cancer Research

Volumn 14, Issue 23, 2008, Pages 7838-7842

  Fieischmann, Achim ^a,d   Schlomm, Thorsten ^b   Huland, Hartwig ^b,c   Köllermann, Jens ^a   Simon, Philipp ^a   Mirlacher, Martina ^a   Salomon, Georg ^b   Chun, Felix H K ^c   Steuber, Thomas ^b   Simon, Ronald ^a   Sauter, Guido ^a   Graefen, Markus ^c   Erbersdobler, Andreas ^a  

^a Department of Pathology ^*  (Germany)

^b Prostate Cancer Center   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; MEMBRANE METALLOENDOPEPTIDASE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SURVIVAL; CELL SURFACE; CLINICAL FEATURE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; TISSUE MICROARRAY; BIOSYNTHESIS; BLOOD; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR;

AGED; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEPRILYSIN; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 59449088722     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1432     Document Type: Article

References (27)

1. Erdos EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 1989;3:145-51.
2. Sumitomo M, Shen R, Nanus DM. Involvement of neutral endopeptidase in neoplastic progression. Bio- chim Biophys Acta 2005;1751:52-9.
3. ZellwegerT, Ninck C, Mirlacher M, et al. Tissue micro-array analysis reveals prognostic significance of syn- decan-1 expression in prostate cancer. Prostate 2003;55:20-9.
4. Freedland SJ, Seligson DB, Liu AY, et al. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate 2003;55: 71 -80.
5. Osman I,Yee H,Taneja SS, et al. Neutral endopeptidase protein expression and prognosis in localized prostate cancer. Clin Cancer Res 2004;10:4096-100.
6. Dall'Era MA, True LD, Siegel AF, Porter MP, Sherertz TM, Liu AY Differential expression of CD10 in prostate cancer and its clinical implication. BMC Urol 2007;7:3.
7. SchlommT, Iwers L, Kirstein P, et al. Clinical significance of EGFR protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res 2007;13:6579-84.
8. Erbersdobler A, Fritz H, Schnoger S, et al. Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone. Eur Urol 2002;41:40-6.
9. Epstein JI, Allsbrook WC, Jr., Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29:1228-42.
10. Bubendorf L, Kononen J, Koivisto P, et al. Survey of gene amplifications during prostate cancer progres-sion by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999;59: 803-6.
11. True L, Coleman I, Hawley S, et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A 2006;103: 10991-6.
12. Liu AY, Roudier MP,True LD. Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. Am J Pathol 2004;165:1543-56.
13. Zheng R, Shen R, Goodman OB, Jr., Nanus DM. Multiple androgen response elements cooperate in androgen regulated activity of the type 1 neutral endopeptidase promoter. Mol Cell Endocrinol 2006;259: 10-21.
14. Usmani BA, ShenR,Janeczko M,et al. Methylation of the neutral endopeptidase gene promoter in human prostate cancers. Clin Cancer Res 2000;6:1664-70.
15. Albrecht M, Doroszewicz J, Gillen S, et al. Proliferation of prostate cancer cells and activity of neutral end opeptidase is regulated by bombesin and IL-1 β with IL-1 βcting as a modulator of cellular differentiation. Prostate 2004;58:82-94.
16. Renneberg H, Albrecht M, Kurek R, et al. Identification and characterization of neutral endopeptidase (EC 3. 4. 24.11) from human prostasomes-localization in prostatic tissue and cell lines. Prostate 2001;46: 173-83.
17. Tawfic S, Niehans GA, Manivel JC. The pattern of CD10 expression in selected pathologic entities of the prostate gland. Hum Pathol 2003;34:450-6.
18. Gomes I, Aumuller G, Wennemuth G, Bette M, Albrecht M. Independent signals determine the subcellular localization of NEP in prostate cancer cells. Biochem Biophys Res Commun 2003;310:919-26.
19. Pulczynski S, Boesen AM, Jensen OM. Antibody-induced modulation and intracellular transport of CD10 and CD19 antigens in human B-cell lines: an immunofluorescence and immunoelectron microscopy study. Blood 1993;81:1549-57.
20. Dall'Era MA, Oudes A, Martin DB, Liu AY. HSP27 and HSP70 interact with CD10 in C4-2 prostatecancer cells. Prostate 2007;67:714-21.
21. Nanus DM. Of peptides and peptidases: the role of cell surface peptidases in cancer. Clin Cancer Res 2003;9:6307-9.
22. Carl-McGrath S, Lendeckel U, Ebert M, Rocken C. Ectopeptidases in tumour biology: a review. Histol Histopathol 2006;21:1339-53.
23. Erhuma M, Kobel M, Mustafa T, et al. Expression of neutral endopeptidase (NEP/CD10) on pancreatic tumor cell lines, pancreatitis and pancreatic tumor tissues. Int J Cancer 2007;120:2393-400.
24. Bunn PA, Jr., Helfrich BA, Brenner DG, et al. Effects of recombinant natural endopeptidase (EC 3.4.24.11) on the growth of lung cancer cell lines in vitro and in vivo. Clin Cancer Res 1998;4:2849-58.
25. Battistini B, Daull P, Jeng AY. CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme. Cardiovasc Drug Rev 2005;23:317-30.
26. Cruden NL, Fox KA, Ludlam CA, Johnston NR, Newby DE. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition. Hypertension 2004;44:913-8.
27. + tumors. Cancer Res 2003; 63:5526-31.